Sanos Group acquires biostatistics specialist Omicron

Clinical contract research organization (CRO) Sanos Group acquires Danish Omicron, which is a successful CRO focusing on biostatistics, data analysis, epidemiology and register-based research.

Sanos Group is a leading clinical contract research and development organization specialized in osteoarthritis, musculoskeletal disorders and skin diseases. The Group comprises all necessary competencies in clinical development and delivers added value to pharma and biotech customers through a simple and efficient business model. Biostatistics are included as a core element in all clinical studies, and historically Sanos Group has collaborated with external partners on this. With the acquisition of Omicron, biostatistics and programming in clinical trials will also become an integral part of Sanos Group.

"The onboarding of Omicron gives us full control of the final part of the value chain in contract research. This makes us a more complete CRO that can offer an even wider range of high-quality integrated research, where we service the entire clinical development of pharmaceuticals. This will further increase our scientific strength across the Group," says CEO Jeppe Ragnar Andersen, Sanos Group.

Sanos Group consists of around 150 employees, primarily in Denmark and the USA, but also in Europe and Hong Kong. The Group has four research clinics, including a Phase 1 unit, and two global full-service CROs, NBCD and Blueskin. They are supported by Studies&Me – a unique digital recruitment platform and tech support for clinical studies – and Sanos Supply, which offers contract manufacturing as well as packaging, labelling, storage and distribution of pharmaceuticals for clinical studies.

Independent entity
Omicron was established in 2019 and consists of more than ten highly educated and specialized consultants such as statisticians and multilingual (SAS, R, SQL etc.) data scientists. The company now relocates to Sanos Group's headquarters in Søborg to enjoy the benefits of being part of a larger group. Omicron will continue unchanged as an independent entity in Sanos Group with the same name and employees. The company will continue under the leadership of founder and CEO Søren Lophaven, who will also join Sanos Group's management team.

"We look forward to persist as biostatistical experts at Sanos Group and continuing our dedicated and value-creating efforts with programming, data analysis and statistics as part of clinical trials at home and abroad," says CEO Søren Lophaven, Omicron.

The parties have agreed not to disclose the purchase price.

Additional Info
Group CEO Jeppe Ragnar Andersen, Sanos Group, +45 7370 8223, jra@sanos.com
CEO Søren Lophaven, Omicron, +45 3029 8747, soren.lophaven@omicron.dk

About Sanos Group
Sanos Group is a leading specialized provider of clinical study services in the global pharma and biotech industry. The group consists of around 150 employees mainly in Denmark and the USA, but also in Europe and Hong Kong, and headquartered in Søborg outside Copenhagen. The group includes Sanos Clinic, which consists of four private research clinics in Denmark, including a phase 1 unit, the two global full-service CROs NBCD and Blueskin, which are supported by Studies&Me, a unique digital recruitment platform and tech support for clinical studies. Sanos Supply offers contract manufacturing as well as packaging, labeling, storage and distribution of pharmaceuticals for clinical studies.

Find more information on www.sanos.com.